Education and Training
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Phase I study of SPARC1023 alone and in combination with carboplatin
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: SPARC1023 I
- drug: SPARC1023 II
Eligibility
Inclusion Criteria:
- Age ≥18 years
- ECOG Performance Status ≤ 1.
- Estimated life expectancy of at least 12-weeks;
- Measurable disease as per RECIST guideline (Version 1.1);
Exclusion Criteria:
- Any malignancy within past 5-years, except non-melanoma skin cancer, cervical
intraepithelial neoplasia, or in situ cervical cancer
- Known hypersensitivity to the study drugs
- Treatment with any anti-cancer agents within 28 days of study entry
- Presence of clinically evident active CNS metastases, including leptomeningeal
involvement, requiring steroid or radiation therapy
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting